BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioLife Solutions, Inc. (BLFS.OB) Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference


9/12/2012 11:44:38 AM

BOTHELL, Wash., Sept. 12, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced its participation at the IBC Inaugural Cell Therapy Clinical Development Conference taking place this week in Arlington, VA.

(Logo: http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

Dr. Aby J. Mathew, Senior Vice President and Chief Technology Officer, presented a lecture to dozens of executives and product development managers of commercial regenerative medicine companies. The presentation, titled, Optimizing Stability and Biopreservation for Cell Therapy Clinical Development and Bioprocessing, exposed the risk to clinical and commercial success of cell and tissue products due to stability limitations from the use of non-optimized storage, transport and cryopreservation freeze media. Compelling comparative data illustrating the superior preservation efficacy of BioLife's HypoThermosol® storage and shipping media, and CryoStor® cryopreservation freeze media was presented on a broad spectrum of cell and tissue types.

Mike Rice, Chief Executive Officer, commented on BioLife's presence and leading supplier position within the regenerative medicine market: "Our participation at this event was validated by numerous other presenters for the first time, confirming to their peers and competitors that they have adopted our best-in-class biopreservation media products. We estimate that more than 60 percent of the companies registered to attend or present are current customers. It's very satisfying to see our quality environment and the ability of our products to improve cell-based therapies being recognized by the leaders in commercial cell therapy development."

For a list of upcoming events, please visit: http://biolifesolutions.com/cell-therapy/category/events/

About BioLife Solutions

BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues. The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced, delayed-onset cell damage and death. BioLife's enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Media Relations:

Investor Relations:


Len Hall

Matt Clawson


Allen & Caron Inc

Allen & Caron Inc


(949) 474-4300

(949) 474-4300


len@allencaron.com

matt@allencaron.com





SOURCE BioLife Solutions, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES